Last reviewed · How we verify
human treated dentin matrix
At a glance
| Generic name | human treated dentin matrix |
|---|---|
| Also known as | human partially demineralized treated dentin matrix |
| Sponsor | nora mostafa mohammed abo shanady |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparative Evaluation of Calcium Silicate-doped Treated Dentin Matrix and Mineral Trioxide Aggregate as Miniature Pulpotomy Biomaterials in Deep Carious Lesions (NA)
- Evaluation of Regenerative Endodontic Treatment for Immature Teeth (NA)
- Tomographic Evaluation of Pulpotomy in Young Permanent Teeth Using Human-treated Dentin Matrix (PHASE1, PHASE2)
- Evaluation of Apexogenesis With Human Treated Dentin Matrix in Young Permanent Molars (PHASE1, PHASE2)
- Treated Dentine Matrix and Platelet Rich Fibrin in Induction of Root Formation of Non-Vital Immature Permanent Teeth (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- human treated dentin matrix CI brief — competitive landscape report
- human treated dentin matrix updates RSS · CI watch RSS
- nora mostafa mohammed abo shanady portfolio CI